






Covid-19 Vaccines Approved in Canada: mRNA vaccines

COVID-19 Formulations	SPIKEVAX™ (Moderna) XBB.1.5		COMIRNATY® (Pfizer) Omicron XBB.1.5	COMIRNATY®(Pfizer) Omicron XBB.1.5	COMIRNATY®(Pfizer) Omicron XBB.1.5	NUVAXOVID™ (Novavax) XBB.1.5
Vaccine Type	mRNA Monovalent		mRNA Monovalent	mRNA Monovalent	mRNA Monovalent	Recombinant protein, adjuvanted
Cap and Label Colour	 Royal Blue cap Coral Blue label		 Maroon cap Maroon label	 Blue cap Blue label	 Grey cap Grey label	 Blue cap White label
Formats available	Multidose (0.10 mg/ml) 10 doses/vial	Multidose (0.10 mg/ml) 5 doses/vial	Multidose (0.015mg/ml) 10 doses after dilution	Multidose (0.033mg/ml) 6 doses/Vial	Multidose (0.1mg/ml) 6 doses/Vial	Multidose 0.01mg/ml 5 doses/Vial
Authorized Age Group	6 months to 11 years	12 years and older	6 Months to 4 years	5 years to 11 years	12 years and older	12 years and older
Dose and Volume	0.25ml 25 mcg	0.5ml 50 mcg	0.2ml 3mcg	0.3ml 10mcg	0.3ml 30mcg	0.5ml 5mcg
Dilution	None		2.2ml/vial	None	None	None
Routine schedule	<p>*1 or 2 doses</p> <p>2 doses: 6m to 4 years of age and previously <u>not</u> vaccinated with second dose at least 4 weeks after the first dose.</p> <p>1 dose: ≥5 years old and previously <u>not</u> vaccinated (or primary series not complete)</p> <p>1 dose: 6 months and older and previously vaccinated (primary series complete)</p>		<p>*1- 3 doses</p> <p>3 doses: 6m to 4 years of age and previously <u>not</u> vaccinated, with second dose at least 3 weeks after the first, followed by a third dose at least 8 weeks after the second dose.</p> <p>1 dose: 6 months to 4 years and previously vaccinated (primary series complete)</p>	<p>*1 dose</p> <p>1 dose: 5 to 11 years old and previously <u>not</u> vaccinated (or primary series not complete)</p> <p>1 dose: 5 to 11 years old and previously vaccinated (primary series complete)</p>	<p>*1 dose</p> <p>1 dose: ≥12 years old and previously <u>not</u> vaccinated (or primary series not complete)</p> <p>1 dose: ≥12 years old and previously vaccinated (primary series complete)</p>	<p>*1 or 2 doses</p> <p>2 doses: ≥12 years old and previously <u>not</u> vaccinated with a second dose at least 3 weeks after the first dose.</p> <p>1 dose: ≥12 years old and previously vaccinated with 1 or more doses</p>
	<p>If <u>primary series complete</u>, the recommended interval is 6 months but a dose of the XBB.1.5 formulation may be administered if it has been at least 3 months from any previous COVID-19 vaccine formulation or known infection.</p> <p>If <u>primary series not complete</u>, a dose can be offered 4 weeks from the last COVID-19 dose or a known SARS-CoV-2 infection (whichever is later).</p>					
	<p>In addition to the fall 2023 dose, the following individuals are now eligible for another dose of XBB.1.5 COVID-19 vaccine, provided it has been at least 3 months from their most recent COVID-19 vaccine dose:</p> <ul style="list-style-type: none"> • Adults 65 years of age and older • Indigenous people 45 years of age and older, including First Nations, Inuit, and Métis peoples, regardless of place of residence • Adult residents of long-term care homes and other congregate living settings for seniors • Individuals 6 months and age and older who are moderately to severely immunocompromised (due to an underlying condition or treatment). 					
	<p>*For moderately to severely immunocompromised people, additional doses may be recommended based on a review of your medical and vaccination history and individual circumstances. A prescription is required for the additional doses.</p>					
Date Authorized	Sept. 12, 2023		Sept. 28, 2023	Sept. 28, 2023	Sept. 28, 2023	Dec.5, 2023
Product Monographs	<p>For links to the Covid-19 vaccine product monographs and resources refer to: Province of Manitoba Information for Health Care Professionals (gov.mb.ca)</p>					

Influenza and Pneumococcal Vaccines Approved for Use in Canada

Formulations	Fluzone [®] Quadrivalent	FluLaval [®] Tetra	Alfurina [®] Tetra	Fluzone [®] High Dose	Pneumovax [®] 23 (Pneu-P-23)
Vaccine Type	IIV4-SD	IIV4-SD	IIV4-SD	IIV4-HD	Pneumococcal polysaccharide 23-valent
Formats Available	0.5 mL single dose prefilled syringe <i>or</i> 5.0 mL multidose vial (10 doses/vial)	5.0 mL multidose vial (10 doses/vial)	0.5 mL single dose prefilled syringe <i>or</i> 5.0 mL multidose vial (10 doses/vial)	0.7 ml Single dose prefilled syringe	0.5 ml single dose prefilled syringe <i>or</i> 0.5 ml single dose vial
Authorized Age Group	6 months and older	6 months and older	<u>5 years and older</u>	65 years and older	**65 years and older
Injection Volume	0.5ml	0.5ml	0.5ml	0.7ml	0.5ml
Dose Schedule	*1 or 2 doses: children 6 months to less than 9 years 1 dose: ≥ 9 years	*1 or 2 doses: children 6 months to less than 9 years 1 dose: ≥ 9 years	*1 or 2 doses: children <u>5 years</u> to less than 9 years 1 dose: ≥ 9 years	1 dose	1 dose
Product Monograph	Fluzone PM	FluLaval PM	Afluria PM	High Dose PM	Pnuemo PM

* Children 6 months to less than 9 years of age who have NOT previously been vaccinated against influenza should receive a second dose of 0.5 mL after an interval of at least 4 weeks.

** Certain high risk criteria is required for those under 65 years of age to be eligible: visit www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.keep.html for more information